Latest News

The treatment landscape for high- and low-risk polycythemia vera is shifting with large scale studies such REVEAL and Low-PV changing practice.

The phase 3 LITESPARK-012 trial failed to meet primary end points of PFS/OS for adding belzutifan or quavonlimab to the standard pembro/lenvatinib doublet.

BBO-11818 has received FDA fast track designation for KRAS-mutant pancreatic cancer, with early phase 1 data showing antitumor activity.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.

mRNA-4359 demonstrated high response rates and antigen-specific T-cell activation in a small cohort of previously untreated patients.

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

A brain-penetrant pan-RAF/MEK molecular glue demonstrated a 38% response rate in a heavily pretreated melanoma population that currently has no approved targeted therapies.

Phase 1 trial of JANX014, a PSMA-targeted T-cell engager, begins in mCRPC, building on prior safety data to expand treatment strategies.

The FDA has granted a priority review to the supplemental biologics license application for enfortumab vedotin/pembrolizumab to all patients with MIBC regardless of cisplatin eligibility.

FDA oncology updates spotlight SCLC ADC review, NRG1 cholangiocarcinoma filing, new glioma PET imaging, and trial restart.

During a live event, Binod Dhakal, MD, discussed the rationale for choosing therapy given before CAR T-cell infusion in multiple myeloma.

Why oncology telehealth stalls: patients cite platform anxiety, few video offers, and in-person trust—pointing to hybrid care.

Combination of interleukin-12 therapy with HAIP chemotherapy showed strong antitumor activity and manageable safety in metastatic CRC with liver metastases.

Darlifarnib may enable the re-challenging of patients with cabozantinib in a combination context for patients with clear cell renal cell carcinoma.

Rezatapopt showed clinical activity across subgroups in patients with TP53 Y220C-mutated ovarian cancer in the phase 2 PYNNACLE trial.

ODD status was granted based on tumor response rates with eftilagimod alfa and pembrolizumab of more than 3-fold above historical benchmarks from radiotherapy alone.

Off-the-shelf CD19 CAR T boosts MRD clearance in first-line LBCL consolidation, with no CRS/ICANS and strong outpatient community feasibility.

Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with manageable safety.

Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists.

Enrollment restarts in a phase 2 ovarian and clear cell gynecologic cancer study after FDA lifts hold on PD-1/CTLA-4 DART therapy.

During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.

NCCN adds mammogram AI risk scoring; a 1.7% five‑year cutoff now prompts earlier screening and optional MRI/ultrasound.

Naomi Haas, MD, shares her insights on the rapidly shifting landscape of adjuvant and neoadjuvant therapies in renal cell carcinoma.

FDA reviews new zenocutuzumab bid for NRG1 fusion cholangiocarcinoma and NCCN adds new recommendations for use of the bispecific antibody.

The FDA granted FTD to OPN-6602, an oral EP300/CBP inhibitor currently used in a first-in-human phase 1 trial.

Tisotumab vedotin plus carboplatin and pembrolizumab ± bevacizumab elicited antitumor acitivity in a phase 1/2 cervical cancer trial.

During a live event, Mark Yarchoan, MD and participants weighed new phase 3 immunotherapy combos for unresectable HCC, balancing survival gains, response durability, and real‑world toxicity challenges.

New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying targeted treatment decisions.

Daraxonrasib nearly doubled median OS vs chemotherapy in pretreated metastatic pancreatic cancer, per phase 3 RASolute 302 trial data.

Community oncology practices can deliver chimeric antigen receptor (CAR) T-cell therapy safely, effectively, and in a sustained manner.

Oral darovasertib plus crizotinib doubled PFS and boosts responses in first-line HLA-A*02:01–negative metastatic uveal melanoma; FDA filing is planned.